Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 1997-2003

  Hecht, J Randolph ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Trarbach, Tanja ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Hainsworth, John D ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Major, Pierre ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Jäger, Elke ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Wolff, Robert A ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Lloyd Salvant, Katherine ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Bodoky, György ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Pendergrass, Kelly ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Berg, William ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Chen, Bee Lian ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Jalava, Tarja ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Meinhardt, Gerold ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Laurent, Dirk ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Lebwohl, David ^{a,b,c,d,e,f,g,h,i,j,k,l,m}   Kerr, David ^{a,b,c,d,e,f,g,h,i,j,k,l,m}  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Virginia Cancer Institute   (United States)

^e Kansas City Cancer Center   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h Medizinische Klinik II   (Germany)

ⁱ BAYER PHARMA AG   (Germany)

^j JURAVINSKI CANCER CENTRE   (Canada)

^k Szent Laszlo Hospital   (Hungary)

^l Bayer Schering Pharma Oy   (Finland)

^m SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LACTATE DEHYDROGENASE; OXALIPLATIN; PLACEBO; VATALANIB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPOKALEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG EMBOLISM; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT REFUSAL; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PHTHALAZINES; PLACEBOS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 79956334386     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.4496     Document Type: Article

References (28)

1. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33-64, 1999 (Pubitemid 29094960)
2. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
3. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000 (Pubitemid 30644117)
4. Takahashi Y, Kitadai Y, Bucana CD, et al: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964-3968, 1995
5. Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25:581-611, 2004
6. Ellis LM, Hicklin DJ: VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591, 2008
7. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
8. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
9. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
10. Hess-Stumpp H, Haberey M, Thierauch KH: PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy. Chembiochem 6:550-557, 2005 (Pubitemid 40868144)
11. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000 (Pubitemid 30225181)
12. Drevs J, Hofmann I, Hugenschmidt H, et al: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60:4819-4824, 2000
13. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003 (Pubitemid 46606209)
14. Mross K, Drevs J, Müller M, et al: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 41:1291-1299, 2005 (Pubitemid 40813005)
15. Joensuu H, De Braud F, Coco P, et al: Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 19:173-177, 2008
16. de Bazelaire C, Alsop DC, George D, et al: Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res 14:5548-5554, 2008
17. Thomas AL, Trarbach T, Bartel C, et al: A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Ann Oncol 18:782-788, 2007 (Pubitemid 46523285)
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. Glusker P, Recht L, Lane B, et al: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980-982, 2006
20. Martín G, Bellido L, Cruz JJ: Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25:3559, 2007 (Pubitemid 47310905)
21. Jost LM, Gschwind HP, Jalava T, et al: Metabolism and disposition of vatalanib (PTK787/ZK- 222584) in cancer patients. Drug Metab Dispos 34:1817-1828, 2006
22. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16:558-565, 2005 (Pubitemid 40613321)
23. Thomas AL, Morgan B, Horsfield MA, et al: Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23:4162-4171, 2005 (Pubitemid 46211322)
24. Van Cutsem E, Bajetta E, Valle J, et al: Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29:2004-2010, 2011
25. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544, 2007 (Pubitemid 46733080)
26. Koukourakis MI, Giatromanolaki A, Simopoulos C, et al: Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis 22:25-30, 2005 (Pubitemid 41185858)
27. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Lactate dehydrogenase 5 expression in operable colorectal cancer: Strong association with survival and activated vascular endothelial growth factor pathway - A report of the Tumour Angiogenesis Research Group. J Clin Oncol 24:4301-4308, 2006 (Pubitemid 46630788)
28. Van Cutsem E, Vervenne WL, Bennouna J, et al: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27: 2231-2237, 2009